文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET代谢与形态体积比预测非小细胞肺癌PD-L1表达及PD-1阻断疗效

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-06-18

研究纳入49例确诊非小细胞肺癌患者,分析18F-FDG PET/CT代谢与形态体积比(MMVR)与PD-L1表达、坏死及抗PD-1/PD-L1治疗疗效的关系。结果显示MMVR与肿瘤细胞PD-L1表达呈负相关,PD-L1表达和低MMVR与临床获益显著相关,坏死与MMVR负相关。

要点

  • MMVR与肿瘤细胞PD-L1表达呈负相关。
  • PD-L1表达和低MMVR与抗PD-1/PD-L1治疗临床获益显著相关。
  • 坏死与MMVR负相关,坏死肿瘤中活化CD8+细胞频率更高。

核心结论

  • MMVR是一种新的影像生物标志物,可无创反映肿瘤PD-L1表达升高并预测非小细胞肺癌检查点阻断的临床获益。

研究设计与样本

  • 研究分析了49例确诊非小细胞肺癌患者的活检或切除标本,通过免疫组化检测PD-L1表达。
  • 从18F-FDG PET/CT图像获取SUVmax、SUVmean、MTV和TLG,计算代谢与形态病灶体积比(MMVR)。
  • 对14例患者通过多重免疫荧光染色分析CD8、PD-1、颗粒酶B和NFATC2,评估坏死与MMVR及肿瘤免疫微环境的关系。

主要发现

  • 共分析25例腺癌和24例鳞状细胞癌,所有肿瘤均显示18F-FDG PET代谢摄取。
  • MMVR与肿瘤细胞PD-L1表达呈负相关。
  • PD-L1表达和低MMVR与临床获益显著相关。
  • 坏死与MMVR呈负相关。
  • 多重免疫荧光显示坏死肿瘤中活化的CD8+细胞频率在间质和上皮肿瘤区域均高于非坏死肿瘤。

临床怎么用

  • MMVR可作为无创影像标志物,辅助预测非小细胞肺癌患者PD-L1表达状态及抗PD-1/PD-L1治疗的临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the correlation between 18F-FDG PET/CT-based markers and tumour tissue expression of PD-L1, necrosis and clinical outcome in patients receiving checkpoint inhibitor treatment. METHODS: PD-Li expression in biopsy or resection specimens from 49 patients with confirmed NSCLC was investigated by immunohistochemistry. Maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were obtained from 18F-FDG PET/CT images. The ratio of metabolic to morphological lesion volumes (MMVR) and its association with PD-L1 expression in each lesion were calculated. The associations between histologically reported necrosis and 18F-FDG PET imaging patterns and radiological outcome (evaluated by iRECIST) following anti-PD-1/PD-L1 therapy were also analysed. In 14 patients, the association between necrosis and MMVR and tumour immune contexture were analysed by multiple immunofluorescent (IF) staining for CD8, PD-1, granzyme B (GrzB) and NFATC2. RESULTS: In total, 25 adenocarcinomas and 24 squamous cell carcinomas were analysed. All tumours showed metabolic 18F-FDG PET uptake. MMVR was correlated inversely with PD-L1 expression in tumour cells. Furthermore, PD-L1 expression and low MMVR were significantly correlated with clinical benefit. Necrosis was correlated negatively with MMVR. Multiplex IF staining showed a greater frequency of activated CD8+ cells in necrotic tumours than in nonnecrotic tumours in both stromal and epithelial tumour compartments. CONCLUSION: This study introduces MMVR as a new imaging biomarker and its ability to noninvasively capture increased PD-L1 tumour expression and predict clinical benefit from checkpoint blockade in NSCLC should be further evaluated.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jreige M, Letovanec I, Chaba K, et al. 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31214790. doi:10.1007/s00259-019-04348-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。